Member of Chinese Academy of Sciences;
Director and Professor, Institute for Immunology, Tsinghua University;
Fellow of the American Association for the Advancement of Science;
The 2009 American Society of Immunologists-BD Biosciences Investigator Award, the 2019 International Cytokine and Interferon Society Biolegend-William E.Paul Award;
Specialty Chief Editor for Frontiers in Immunology, T Cell Biology, Associate Chief Editor for China Science Life Sciences, and Editorial Board Member of Immunity;
Published more than 200 papers in immunology field, and was recognized as a “Highly Cited Scientist” in the world for seven consecutive years from 2014 to 2020.
Chief Clinical Expert, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences；
Special allowance experts from the State Council and young and middle-aged experts from the National Health Commission；
Member of the International Myeloma Society (IMS)；
Member of the Expert Committee of the International Myeloma Working Group (IMWG)；
Editorial Board of Blood Advances;
Chairman of the Myeloma Expert Committee, Chinese Society of Clinical Oncology (CSCO);
Standing Council Member of the Chinese Anti-Cancer Association (CACA) and Chairman of the Integrated Rehabilitation Committee for Hematologic Tumors, CACA;
Vice President of the 6th Tianjin Anti-Cancer Association Council;
Editorial Board of 6 Core Journals such as Chinese Journal of Hematology;
More than 30 fund projects such as the key projects of the National Science and Technology Support Plan and the key projects of the National Natural Science Foundation of China have been completed;
Nearly 600 papers have been published, including more than 160 SCI papers;6 monographs; 6 national invention patents;
Won 2 first prizes of provincial and ministerial achievements.
Nikhil C. Munshi, M.D. is the Kraft Family Chair and Professor of Medicine at the Harvard Medical School and the Director of Basic and Correlative Science, at the Jerome Lipper Myeloma Center at the Dana Farber Cancer Institute. He is a senior physician at the Brigham and Women’s Hospital, Harvard Medical School. Professor Munshi studied medicine at the S.S.G. Hospital and M.S. University, in Baroda, India, before completing fellowships in oncology at the Johns Hopkins Oncology Center, Baltimore, MD, USA, and the Indiana University Medical Center, Indianapolis, IN, USA.
His research focus spans both basic sciences to understand genomic changes in myeloma and elucidate molecular mechanisms driving the genomic instability in cancer, to translational approaches directed at improving diagnosis and prognosis as well as therapeutics. Dr Munshi’s clinical interests include CAR T-cell therapy in multiple myeloma and developing novel targeted therapeutics including novel antigen-directed and immune effector cell therapy/vaccine approaches.
He has over 500 peer-reviewed publications and book chapters. Dr. Munshi has mentored over 70 junior faculty, post-doctoral fellows, medical residents. A number of them are now independent scientists, physicians, and professionals. He is the immediate former President of the International Myeloma Society. He has received number of Awards including the Dr. B.C. Roy National Award by the president of India in 2016, the prestigious “Waldenstrom’s Award” for Most Distinguished Lifetime Achievement in Myeloma Research in 2013, the COMy “Multiple Myeloma Excellence Award for Translational Research” in 2019 and Robert Kyle Award in 2021.
Philippe Moreau, MD, serves as Professor of Clinical Hematology at the University Hospital of Nantes, France. Professor Moreau’s clinical interests are focused on multiple myeloma and its treatment with high-dose therapy and novel agents.
Professor Moreau is president of International Myeloma Society (IMS) since 2023, and he is a member of the steering committee of the International Myeloma Working Group (IMWG) since 2013. He has served as the principal investigator of several international clinical trials evaluating new drugs and new immunotherapies. He was a member of the organizing committee for the 2011 International Myeloma Workshop in Paris, and was the chairman of the French cooperative group IFM from 2006 to 2009 and from 2020 to 2023.
His research is widely published, with more than 600 peer-reviewed articles and reviews that have appeared in high impact factor journals including New England Journal of Medicine, The Lancet, Journal of Clinical Oncology, Lancet Oncology, or Blood. He is frequently invited speaker at international hematologic oncology meetings, and during Educational Session on Multiple Myeloma at ASH, ASCO or EHA. Professor Moreau received in 2018 the Robert A. Kyle lifetime achievement award. He is a member of Academia Europaea.
